Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

Peter C Fong, Timothy A Yap, David S Boss, Craig P Carden, Marja Mergui-Roelvink, Charles Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou, Roger A'Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H M Schellens, Johann S de Bono, Stan B Kaye

Research output: Contribution to journalArticlepeer-review

Abstract

Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair. Platinum-based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers.
Original languageEnglish
Pages (from-to)2512-9
Number of pages8
JournalJournal of Clinical Oncology
Volume28
Issue number15
DOIs
Publication statusPublished - 2010

Fingerprint

Dive into the research topics of 'Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval'. Together they form a unique fingerprint.

Cite this